Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb 18;15(2):e25639.
doi: 10.5812/hepatmon.25639. eCollection 2015 Feb.

Telaprevir experience from Turkey

Suheyla Komur  1 , Behice Kurtaran  1 , Ayse Seza Inal  1 , Husnu Pullukcu  2 , Aslihan Ulu  1 , Ferit Kuscu  3 , Tansu Yamazhan  2 , Yesim Tasova  1 , Hasan Salih Zeki Aksu  1
Affiliations

Telaprevir experience from Turkey

Suheyla Komur et al. Hepat Mon. .

Abstract

Background: In patients with chronic hepatitis C, triple drug regimens containing a protease inhibitor, peginterferon and ribavirin were found to significantly increase sustained virologic response rates compared to dual drug regimen containing pegylated interferon and ribavirin, especially in genotype 1.

Objectives: In Turkey, telaprevir has been used since March 2013. We aimed to evaluate results of patients with chronic hepatitis C treated with telaprevir, peginterferon and ribavirin.

Patients and methods: We evaluated 28 patients with genotype 1 chronic hepatitis C infection treated with triple drug regimen containing telaprevir, in three medical centers in Turkey, retrospectively. Demographic data of patients, treatment indications, adverse events and outcomes were recorded.

Results: Of 28 patients intended to treat, 25 (89.2%) patients completed the treatment. Overall, 21 (82.1%) patients had relapse and five patients were non-responder. Regarding the treatment outcomes of Telaprevir based regimen, 20/26 patients achieved sustained virological response. Pruritus, rash, dysgeusia, anorectal discomfort and anemia were main adverse effects. Blood transfusion and ribavirin dose reduction required for 7 and 11 patients, respectively. Due to several adverse effects, 10 patients were hospitalized.

Conclusions: Although more frequent and severe adverse effects, telaprevir has been promising for patients with treatment-experienced hepatitis C.

Keywords: Genotype 1; Hepatitis C; Telaprevir; Turkey.

PubMed Disclaimer

References

    1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74–81. doi: 10.1111/j.1478-3231.2008.01934.x. - DOI - PubMed
    1. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20(1):17–35. - PubMed
    1. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245–64. doi: 10.1016/j.jhep.2011.02.023. - DOI - PubMed
    1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–44. doi: 10.1002/hep.24641. - DOI - PMC - PubMed
    1. Park C, Jiang S, Lawson KA. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther. 2014;39(1):14–24. doi: 10.1111/jcpt.12106. - DOI - PubMed

LinkOut - more resources